Johnson & Johnson announces psoriasis study shows preference for oral treatments

Johnson & Johnson announced findings from the U.S. dataset from the global ENCOMPASS study evaluating patient and healthcare provider perspectives on barriers and unmet needs in psoriasis care. The results, presented at the 2025 Fall Clinical Dermatology Conference, reveal significant unmet needs and a strong preference for oral treatment options that achieve treatment goals with high efficacy and favorable safety. The findings help to characterize the clinical profile of patients, quantify disease burden, evaluate treatment preferences and goals, and assess the impact of psoriasis on patient quality of life using the Dermatology Life Quality Index. Key findings show that psoriasis imposes a significant disease burden, profoundly affecting patient QoL. QoL impact was even higher among adolescents: 71% of those aged 16-17 years and 77% of those aged 12-15 years reported a very large or extremely large QoL impact. Perceived disease burden was primarily influenced by: skin symptoms, severity, lesion location, lack of effective treatments, impact on social activities and mental health. Study findings also gauged key treatment preferences among adult patients and dermatology HCPs. Oral treatment was preferred among both patients and HCPs – 50.5% and 47.5%, respectively -, followed by topicals – 34.3% and 20.0% – and injectables – 15.3% and 22.0% -. Providers indicated they would prefer an oral therapy if efficacy, safety and tolerability were equivalent among the modes of administration. Of patients currently treated with injectables, 91.2% expressed willingness to switch to an equally effective new oral treatment with favorable safety.